Astellas Pharma (4503) Sustainable Meeting 2024 summary

Opening and context

• The meeting focused on the relationship between sustainability initiatives and enterprise value, with presentations from key executives and directors.

• Forward-looking statements were made, subject to risks and uncertainties, and simultaneous interpretation was provided.

Organizational health and innovation

• Organizational Health Goals (OHG) targeted innovation, talent and leadership, and unity across divisions.

• Accelerated global regulatory submissions for VYLOY, achieving 13 submissions in FY2023, with approvals in 30 countries and launches in nine.

• Next Generation Leadership Program developed 50 high-potential leaders, with four proposals moving to business projects.

• Employee engagement scores declined to 69, attributed to rapid organizational changes and communication gaps.

• A task force was formed to address communication and engagement, focusing on management education and change management.

Social impact and non-financial value

• Quantified the social impact of a cancer awareness program in Malaysia, estimating a $4.6 million value from a $1 million input, mainly through medical and psychological benefits.

• Used advanced analytics to link non-financial indicators—such as female manager ratio and governance metrics—to market capitalization.

• Found that a higher percentage of female managers (25–40%) correlates with increased market cap, while a higher ratio of managers (organizational layers) negatively impacts it.

• Identified four human capital and two governance indicators as significant contributors to enterprise value.